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Abstract
Background: Recent studies have suggested the importance of HLA genes in determining immune responses following
rubella vaccine. The telomeric class III region of the HLA complex harbors several genes, including lymphotoxin alpha (LTA),
tumor necrosis factor (TNF) and leukocyte specific transcript -1 (LST1) genes, located between the class I B and class II DRB1
loci. Apart from HLA, little is known about the effect of this extended genetic region on HLA haplotypic backgrounds as
applied to immune responses.
Methodology/Principal Findings: We examined the association between immune responses and extended class I-class II-
class III haplotypes among 714 healthy children after two doses of rubella vaccination. These extended haplotypes were
then compared to the HLA-only haplotypes. The most significant association was observed between haplotypes extending
across the HLA class I region, ten-SNP haplotypes, and the HLA class II region (i.e. A-C-B-LTA-TNF-LST1-DRB1-DQA1-DQB1-
DPA1-DPB1) and rubella-specific antibodies (global p-value of 0.03). Associations were found between both extended A*02-
C*03-B*15-AAAACGGGGC-DRB1*04-DQA1*03-DQB1*03-DPA1*01-DPB1*04 (p=0.002) and HLA-only A*02-C*03-B*15-
DRB1*04-DQA1*03-DQB1*03-DPA1*01-DPB1*04 haplotypes (p=0.009) and higher levels of rubella antibodies. The class II
HLA-only haplotype DRB1*13-DQA1*01-DQB1*06-DPA1*01-DPB1*04 (p=0.04) lacking LTA-TNF-LST1 SNPs was associated
with lower rubella antibody responses. Similarly, the class I-class II HLA-only A*01-C*07-B*08-DRB1*03-DQA1*05-DQB1*02-
DPA1*01-DPB1*04 haplotype was associated with increased TNF-a secretion levels (p=0.009). In contrast, the extended
AAAACGGGGC-DRB1*01-DQA1*01-DQB1*05-DPA1*01-DPB1*04 (p=0.01) haplotype was found to trend with decreased
rubella-specific IL-6 secretion levels.
Conclusions/Significance: These data suggest the importance of examining both HLA genes and genes in the class III
region as part of the extended haplotypes useful in understanding genomic drivers regulating immune responses to rubella
vaccine.
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Introduction
Studies conducted by others and ourselves have supported the
importance of HLA genes in determining both humoral and
cellular immune responses to rubella vaccine. For example, the
HLA class II genes, and particularly the DRB1*04-DQB1*03-
DPB1*03 and DRB1*15/16-DQB1*06-DPB1*03 haplotypes sig-
nificantly influence rubella-specific antibody responses [1]. Evi-
dence continues to accumulate however, that the immune
response to viral vaccines is controlled by more than just HLA-
specific polymorphisms. In fact, a large and growing family of non-
HLA genes has recently been identified as critical to the immune
response to vaccination, including rubella [2–4]. Recent studies
support the idea that polymorphisms in immune-response
candidate-genes should be analyzed as haplotypes rather than as
individual alleles based on evidence for multigenic control of
immune responses to infectious pathogens [5–7].
Several genes encoded in the class III region of the HLA
complex on chromosome 6 (6p21.3) - including lymphotoxin alpha
(LTA), tumor necrosis factor (TNF) and leukocyte specific
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11806transcript -1 (LST1) genes – are linked between the HLA-B and
HLA-DRB1 loci [8]. Because of their linkage to HLA class I and II
genes, it has been suggested that TNF and/or LTA (and LST1)
may contribute to combinations or haplotypes of allelic variants
that differ in composition and occurrence, and may contribute to
the etiology of HLA-associated infectious diseases and immunity
[5,8,9]. Studies have associated specific single nucleotide poly-
morphisms (SNPs) in either the TNF or LTA locus, along with
HLA-B and/or HLA-DRB1 loci, with severe dengue virus
infection, malaria, and susceptibility to autoimmune diseases
[5,6,10]; however, extended LTA, TNF, LST1, and class I and
class II HLA haplotype associations with rubella vaccine-induced
immune responses have not been examined.
TNF and LTA are proinflammatory cytokines with important
biological activities and immunomodulatory functions and are
known to influence a variety of cellular responses [11]. Polymorph-
isms in the genes encoding TNF and LTA appear to contribute to
infectious disease susceptibility and infection [12–16]. The leuko-
cyte specific transcript-1 is a gene with extensive alternative splicing
and is encoded within the TNF region of the HLA complex, and
plays a role in inflammatory and infectious diseases [17,18]. The
LST1 gene is constitutively expressed in PBMCs and has an
inhibitory effect on lymphocyte proliferation [17]. Hence, LTA,
TNF, LST1, and additional genes encoded in the telomeric class III
HLA region are potentially important genetic markers of vaccine-
inducedimmunity.Wesought totestthehypothesisthatinclusionof
class III genes in extended class I-class II gene haplotypes provides
information beyond HLA alone. For this reason we investigated
associations between rubella-specific antibody and cytokine levels
with 33 haplotypes containing polymorphisms for LTA, TNF, and
LST1 candidate genes. We analyzed extended SNP-defined LTA,
TNF, LST1, and HLA haplotype profiles and examined their
contribution to humoral and cellular immune responses following
the recommended two doses of the US licensed rubella-containing
vaccine. This builds upon the work on HLA-only haplotype
associations that we previously reported [1,19,20].
Results
Associations between Extended Haplotypes and Rubella-
Specific Antibodies
As previously reported, we genotyped 714 healthy adolescents
and young adults (336 females and 378 males) following two doses
of rubella vaccine [21]. Summaries of demographic and clinical
characteristics for these subjects can be found in Table 1. The
median rubella-specific antibody level in our study cohort was 34.5
(IQR 19.2–63.7) IU/ml. We previously examined associations
between HLA haplotypes and rubella antibody levels and found
that class I A*01-C*07-B*07 (p=0.04) and A*03-C*07-B*07
(p=0.04) haplotypes were associated with higher and lower
rubella-specific IgG antibodies, respectively [20]. Further, we
found that the class II DRB1*04-DQB1*03-DPB1*03 (p=0.01)
and DRB1*15/16-DQB1*06-DPB1*03 (p=0.005) haplotypes
were associated with lower levels of IgG antibodies [20].
Testing the hypothesis that our further extended haplotypes
provide information beyond the HLA haplotypes, separate analyses
were performed for each of three sets of combinations or extended
haplotypes: one containing the three class I HLA loci (A-C-B) and
the set of ten-SNP haplotypes, one containing ten-SNP haplotypes
and the class II HLA loci (DRB1-DQA1-DQB1-DPA1-DPB1), and
one containing class I HLA loci (A-C-B), the set of ten-SNP
haplotypes, and the class II HLAloci (DRB1-DQA1-DQB1-DPA1-
DPB1) (Figure 1). To examine our hypothesis, these sets of
extended haplotypes were compared to the HLA-only haplotypes.
A total of 12 extended haplotypes with frequencies of $1%
were identified in the first set of allelic combinations. Table 2
shows specific haplotypes with significant (p,0.05) or suggestive
(p#0.15) associations with rubella IgG antibody levels. The global
test for association failed to show a statistically significant
association between haplotypes extending across the class I HLA
region and the set of ten-SNP haplotypes and rubella antibody
levels (p-value of 0.29). While this difference is not statistically
significant, given the lack of global significance, several observa-
tions are of potential interest. When examining extended HLA
class I, LTA, TNF, and LST1 haplotypes individually, the A*02-
C*03-B*15-AAAACGGGGC(test statistic of 2.54, p=0.01) and
A*03-C*07-B*07-GGTGCAGGAC (test statistic of 22.34,
p=0.02) haplotypes trended with higher and lower rubella
humoral antibody responses, respectively. Among these individu-
ally statistically significant extended haplotypes, the class I HLA-
only haplotype A*03-C*07-B*07 (test statistic of -2.60, p=0.01)
was also associated with lower rubella antibodies, indicating that
inclusion of LTA-TNF-LST1 SNPs did not substantially change
the strength of this genetic association. By contrast, the HLA-only
haplotype A*02-C*03-B*15 lacking SNPs demonstrated no
association with rubella-specific antibodies (p=0.15).
A total of 15 extended haplotypes with frequencies of $1% were
identified in the second set of allelic combinations. For the extended
LTA, TNF, LST1, and HLA class II region haplotypes, the global
test did not reach statistical significance (p-value of 0.11). The
individual haplotype with the strongest numerical value for
association with higher rubella-specific antibody response was AAA-
ACGGGGC-DRB1*04-DQA1*03-DQB1*03-DPA1*01-DPB1*04
(test statistic of 2.31, p=0.02). We also found trends for lower levels
of rubella-specific antibody marginally associated with the
AAAACGGGGC-*01*01*05*01*04 haplotype (test statistic of
1.68, p=0.09). For HLA-only haplotypes and rubella antibodies,
Table 1. Demographic characteristics of the study population
(n=714).
Variable Category No. of subjects (%)
Overall 714
Age at enrollment 11–13 years 212 (29.7%)
14–15 years 190 (26.6%)
16–17 yeas 200 (28.0%)
18–19 yeas 112 (15.7%)
Age at first rubella vaccination ,=14 months 89 (12.5%)
15 months 384 (53.8%)
16–17 months 119 (16.6%)
.=18 months 122 (17.1%)
Age at second rubella vaccination ,=5 years 205 (28.7%)
6–10 years 109 (15.3%)
11 years 122 (17.1%)
.=12 years 278 (38.9%)
Gender Female 336 (47.1%)
Male 378 (52.9%)
Race Other 65 (9.1%)
White 649 (90.9%)
Cohort First 324 (45.4%)
Second 390 (54.6%)
doi:10.1371/journal.pone.0011806.t001
Extended Gene Haplotypes
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II HLA-only haplotype DRB1*13-DQA1*01-DQB1*06-DPA1*01-
DPB1*04 (test statistic of 22.07, p=0.04), while neither DRB1*04-
DQA1*03-DQB1*03-DPA1*01-DPB1*04 (p=0.10) nor *01*01*
05*01*04 (p=0.5) showed any trend.
A total of 6 extended haplotypes with frequencies of $1% were
identified in the third set of allelic combinations. The most
significant association was observed between these haplotypes
extending across the HLA class I region, ten-SNP haplotypes, and
the HLA class II region (i.e. A-C-B-LTA-TNF-LST1-DRB1-
DQA1-DQB1-DPA1-DPB1) and rubella virus-specific antibodies
(global p-value of 0.03). We found haplotypes associated with very
high humoral immune response among rubella-vaccinated indivi-
duals. The specific haplotype with the strongest association was
A*02-C*03-B*15-AAAACGGGGC-DRB1*04-DQA1*03-DQB1*
03-DPA1*01-DPB1*04 (test statistic of 3.16, p=0.002). Similarly,
the HLA-only A*02-C*03-B*15-DRB1*04-DQA1*03-DQB1*03-
DPA1*01-DPB1*04 haplotype (test statistic of 2.62, p=0.009) was
significantly associated with high rubella humoral immune response
(Table 2). These associations were slightly stronger when including
the set of ten-SNP haplotypes.
Associations between Extended HLA class I, LTA, TNF,
LST1 Haplotypes and Rubella-Specific Cytokines
We previously examined associations of HLA haplotypes with
rubella-specific cytokine production and found that several class I
haplotypes were potentially associated with variations in cytokine
secretion levels [19]. In our study the overall cytokine profile was
skewed towards a predominant Th1/inflammatory response as
previously described [21]. Median values (IQR) for rubella-specific
IFN-c, IL-2, IL-6, TNF-a, and GM-CSF cytokine secretion levels
were 8.5 (3.0, 23.4) pg/ml, 17.6 (7.7, 30.5) pg/ml, 3681.0 (3160.0,
4052.0) pg/ml, 29.7 (27.0, 89.2) pg/ml, and 28.0 (23.6, 32.6) pg/
ml, respectively. A total of 12 haplotypes extending across the class
I region (i.e. A-C-B-LTA-TNF-LST1) with frequencies of $1%
were identified. Tables 3–5 only report haplotypes with
significant (p,0.05) or suggestive (p#0.15) associations with
rubella virus-specific secreted cytokines.
Separate analyses were performed for every measure of cytokine
response (IFN-c, IL-2, IL-6, TNF-a, and GM-CSF). The global
tests for association failed to show a statistically significant
association between allelic combinations and rubella-specific
cytokine responses measured by ELISA (Table 3). When
examining haplotypes individually, the class I extended A*02-
C*07-B*07-GGTGCAGGAC (t-statistic of 22.12, p=0.03) and
A*01-C*06-B*57-AGTGCGGGGC(t-statistic of 22.01, p=0.04)
haplotypes were suggestive of lower rubella-specific IL-2 and IL-6
cytokine responses, respectively.
We found no associations between class I HLA-only haplotypes
and lower rubella-specific cytokine responses. On the contrary,
we found trends for higher levels of IFN-c and IL-6 associated
with class I HLA-only haplotypes such as A*03-C*04-B*35 (t-
statistic of 2.32, p=0.02) and A*24-C*07-B*07 (t-statistic of 2.64,
p=0.009), respectively. We found no evidence that LTA-TNF-
LST1 alleles alter the strengths of the genetic associations
between extended haplotypes and rubella-specific IFN-c and
IL-6.
We also found trends for higher levels of the inflammatory
cytokine, TNF-a, associated with both the extended haplotype
A*29-C*16-B*44-GGTGCAGGA (t-statistic of 2.30, p=0.02) and
the HLA-only haplotype A*29-C*16-B*44 (t-statistic of 2.35,
p=0.02).
However, these findings should be interpreted with caution, due
to the lack of a significant global test result.
Figure 1. A schematic overview of the extended human leukocyte antigen (HLA) complex, encompassing the lymphotoxin alpha
(LTA), tumor necrosis factor (TNF) and leukocyte specific transcript -1 (LST1) genes on chromosome 6 (6p21.3). A 3,145 kb segment of
the extended HLA gene region is shown. The LTA, TNF, and LST1 loci encoded in the class III region of the HLA complex in relation to HLA-B and HLA-
DRB1 loci. The positions of single nucleotide polymorphisms (SNPs) selected from LTA [rs2857602 (31641357), rs2857708 (31641585), rs915654
(31646476), rs2844482 (31647746), rs1041981 (31648763), rs1799964 (31650287), rs1799724 (31650461)], TNF [rs1800629 (31651010)], and LST1
[rs2256965 (31663109), rs2256974 (31663371)] gene families and used for haplotype estimation are shown. Targeted sets of extended haplotypes
used in this study: (1) haplotypes containing the three class I HLA loci (A-C-B) and the set of ten-SNP haplotypes, (2) haplotypes containing ten-SNP
haplotypes and the class II HLA loci (DRB1-DQA1-DQB1-DPA1-DPB1), and (3) haplotypes containing class I HLA loci (A-C-B), the set of ten-SNP
haplotypes, and alleles of class II HLA loci (DRB1-DQA1-DQB1-DPA1-DPB1). Note: the figure is not to scale.
doi:10.1371/journal.pone.0011806.g001
Extended Gene Haplotypes
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Class II Haplotypes and Rubella-Specific Cytokines
We previously also examined associations of HLA haplotypes
with rubella-specific cytokine production and found that several
class II haplotypes were potentially associated with variations in
cytokine secretion levels [19]. In this study a total of 15 extended
haplotypes (i.e. LTA-TNF-LST1-DRB1-DQA1-DQB1-DPA1-
DPB1) with frequencies of $1% were identified. The five global
tests failed to show a statistically significant association between
SNPs in LTA, TNF and LST1 genes and across the class II HLA
haplotypes and rubella-specific IFN-c, IL-2, TNF-a, and GM-
CSF, although for the haplotypes and IL-6 secretion the global p-
value was suggestive but not statistically significant (p=0.05)
(Table 4).
The extended AAAACGGGGC-DRB1*01-DQA1*01-DQB1*05-
DPA1*01-DPB1*04 haplotype (t-statistic of 22.53, p=0.01) was
observed to trend with decreased rubella-specific IL-6 secretion levels.
We also found trends for lower levels of IL-6 secretion associated with
the class II HLA-only DRB1*03-DQA1*05-DQB1*02-DPA1*01-
DPB1*04 haplotype (t-statistic of 22.07, p=0.04). In contrast, the
AGTGAAGAGC-DRB1*15-DQA1*01-DQB1*06-DPA1*01-DPB1*
04 haplotype (t-statistic of 1.95, p=0.05) was found to trend with
increased IL-6 secretion levels.
We also found trends for higher levels of IFN-c secretion associ-
ated with the extended GGTGCAGGAC-DRB1*04-DQA1*
03-DQB1*03-DPA1*01-DPB1*04 haplotype (t-statistic of 2.09,
p=0.04). On the contrary, two extended AGTGAAGAGC-
DRB1*15-DQA1*01-DQB1*06-DPA1*01-DPB1*04 (t-statistic of
22.01, p=0.04) and AGAGAAGGGA-DRB1*13-DQA1*01-
DQB1*06-DPA1*01-DPB1*04 (t-statistic of 22.73, p=0.006) hap-
lotypes were observed to be significantly associated with decreased
rubella-specific IFN-c secretion levels. We found no associations
between class II HLA-only haplotypes and variations in rubella-
specificIFN-ccytokine responses.Inaddition,theindividualextended
haplotype with statistical evidence of a support for trend toward
an association with higher IL-2 responses was AGAGAAGG-
GA-DRB1*04-DQA1*03-DQB1*03-DPA1*01-DPB1*04 (t-statistic
of 2.49, p=0.01). The class II HLA-only DRB1*04-DQA1*03-
DQB1*03-DPA1*01-DPB1*04 haplotype (t-statistic of 2.87, p=
0.004) was also observed to be significantly associated with increased
rubella-specific IL-2 secretion levels, suggesting that LTA-TNF-
LST1 SNPs are not contributing to the effect of IL-2 response
associations.
Finally, we also found trends for lower levels of inflammatory
GM-CSF with the extended AAAACGGGGC- DRB1*01-DQA1*
01-DQB1*05-DPA1*01-DPB1*04 haplotype (t-statistic of 22.09,
p=0.04). However, these associations must be considered pre-
liminary given the absence of a significant global test result. Neither
rubella-specific GM-CSF secretion nor TNF-a secretion levels were
associated with class II HLA-only haplotypes.
Associations between Extended HLA Class I, LTA, TNF,
LST1, HLA Class II Haplotypes and Rubella-Specific
Cytokines
A total of 6 haplotypes extending across the class I and II regions
(i.e. A-C-B-LTA-TNF-LST1-DRB1-DQA1-DQB1-DPA1-DPB1)
with frequencies of $1% were identified. Associations between
HLA class I and class II haplotypic backgrounds with LTA-TNF-
Table 2. Associations between extended haplotypes and HLA-only haplotypes, and rubella virus-specific antibody responses.
Class, haplotype Haplotype
b
Haplotype
frequency
Test statistic
(haplotype
t-statistic)
Allele
p-value
a
Global
p-value
HLA-only
haplotype
frequency
Test statistic
(haplotype
t-statistic)
Allele
p-value
a
Global
p-value
A-C-B-RS2857602-RS2857708-RS915654-RS2844482-RS1041981-RS1799964-RS1799724-RS1800629-RS2256965-RS2256974
A-C-B-LTA-TNF-LST1 0.288 0.159
*02*03*15-AAAACGGGGC 0.026 2.54 0.011 0.039 1.44 0.151
03*07*07-GGTGCAGGAC 0.050 22.34 0.020 0.056 22.60 0.010
RS2857602-RS2857708-RS915654-RS2844482-RS1041981-RS1799964-RS1799724-RS1800629-RS2256965-RS2256974-DRB1-DQA1-DQB1-DPA1-DPB1
LTA-TNF-LST1-
DRB1-DQA1-DQB1-
DPA1-DPB1
0.107 0.035
AGAGAAGGGA-
*13*01*06*01*04
0.012 21.46 0.146 0.042 22.07 0.039
AAAACGGGGC-
*01*01*05*01*04
0.022 1.68 0.093 0.055 0.64 0.522
AAAACGGGGC-
*04*03*03*01*04
0.024 2.31 0.021 0.100 1.66 0.098
A-C-B-RS2857602-RS2857708-RS915654-RS2844482-RS1041981-RS1799964-RS1799724-RS1800629-RS2256965-RS2256974-DRB1-DQA1-DQB1-DPA1-DPB1
A-C-B-LTA-TNF-LST1-
DRB1-DQA1-DQB1-
DPA1-DPB1
0.033 0.168
*02*03*15-AAAACGGGGC-
*04*03*03*01*04
0.013 3.16 0.002 0.018 2.62 0.009
Only haplotypes with estimated frequencies $0.01 and p-values #0.15 are presented.
aHaplotype effects estimated using a haplotype t-statistic that assesses associations of antibody levels across haplotypes. Allele p-value compares the haplotype of
interest to all other haplotypes combined. Statistically significant findings (p,0.05) are shown in bold. Analyses adjust for age at blood draw, gender, race, age at first
rubella vaccine, age at second rubella vaccine, and cohort status.
bCommon SNPs from the LTA gene: [rs2857602 (A.G), rs2857708 (G.A), rs915654 (T.A), rs2844482 (G.A), rs1041981 (C.A), rs1799964 (A.G), rs1799724 (G.A)]; TNF
gene: rs1800629 (G.A); LST1 gene: [rs2256965 (G.A), and rs2256974 (C.A)].
doi:10.1371/journal.pone.0011806.t002
Extended Gene Haplotypes
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presented in Table 5. Global tests failed to find significant
associations between extended haplotypes and rubella-specific TNF-
a secretion (p-value of 0.06). However, the A*01-C*07-B*08-
AGTGAAGAGC-DRB1*03-DQA1*05-DQB1*02-DPA1*01-DPB1*
04 haplotype (t-statistic of 2.53, p=0.01) was found to be associated
with increased TNF-a secretion levels. Conversely, the global tests
suggested associations between TNF-a secretion and class I-class II
HLA-only haplotypes (p-value of 0.04). Specifically, the A*01-C*07-
B*08-DRB1*03-DQA1*05-DQB1*02-DPA1*01-DPB1*04 haplotype
(t-statistic of 2.64, p=0.009) was significantly associated with increased
TNF-asecretionlevels. Thissuggeststhatthese associationswere mostly
driven by HLA gene polymorphisms and not by the LTA-TNF-LST1
alleles per se.
The global tests failed to provide evidence of statistically significant
associations between extended haplotypes and IFN-c,I L - 2 ,I L - 6 ,a n d
GM-CSF production. However, individual HLA-only haplotypes
associated with lower and higher rubella-specific IFN-c responses
included A*03-C*07-B*07-DRB1*15-DQA1*01-DQB1*06-DPA1*01-
DPB1*04 (t-statistic of -2.57, p=0.01) and A*02-C*07-B*07-DRB1*15-
DQA1*01-DQB1*06-DPA1*01-DPB1*04 (t-statistic of 2.26, p=0.02),
respectively. No significant associations were detected between IFN-c,
IL-2, and GM-CSF production and any haplotype extending across the
class I and II regions.
Discussion
The HLA genes significantly impact an individual’s ability to
respond immunologically to rubella vaccine antigens because
binding of antigenic peptides occurs within the HLA peptide
binding groove, and the repertoire of bound peptides depends on
HLA allele-specific polymorphisms [22,23]. However, HLA gene
polymorphisms alone do not explain the entire vaccine-induced
immune response. Consistent with the evidence away from a single
dominant allele model for complex immune responses, and toward
a multigenic network model [24], this study was undertaken to
further explore the extent of genetic polymorphisms within the
LTA, TNF, LST1, and HLA regions and to expand our under-
standing of immunogenetic mechanisms of rubella vaccine-induced
immunityacrossa largergeneticregionofinterest.Wehypothesized
that the gene products encoded in the HLA region on chromosome
6 operate jointly with other genes to determine rubella vaccine
immune response outcomes. A total of 33 unique LTA-TNF-LST1-
HLAhaplotypes wereidentified. Class I and class II HLAhaplotype
associations between antibody, cytokine levels, lymphocyte pro-
liferative, and ELISPOT responses following rubella vaccine have
been described [1,19,20]. We studied additional genetic markers
(SNPs) included in HLA haplotypes, including ten-SNP common
polymorphisms, located between HLA-B and HLA-DRB1 loci.
The specific extended haplotype with the strongest association
with higher humoral immune response among rubella-vaccinated
subjects was A*02-C*03-B*15-AAAACGGGGC-DRB1*04-DQA1*
03-DQB1*03-DPA1*01-DPB1*04 (p=0.002). Similarly, the HLA-
only haplotype A*02-C*03-B*15-DRB1*04-DQA1*03-DQB1*03-
DPA1*01-DPB1*04 (p=0.009) was also associated with higher
humoral immune response. Importantly, the relative comparison of
global tests and individual p-values between haplotypes demonstrated
slightly stronger associations when including the set of ten-SNP
haplotypes.
This particular extended haplotype may be considered a highly
significant immune (antibody) response haplotype to rubella virus
vaccine. Additionally, two extended (A*02-C*03-B*15-AAAAC-
GGGGC, p=0.01 and AAAACGGGGC-DRB1*04-DQA1*03-
DQB1*03-DPA1*01-DPB1*04, p=0.02) haplotypes trended with
higher rubella antibody responses. Effects attributable to these
haplotypes were due in part to LTA-TNF-LST1 SNPs, because the
Table 3. Associations between extended class I-HLA-LTA-TNF-LST1 haplotypes and class I HLA-only haplotypes, and rubella-
specific cytokine responses.
Cytokine Haplotype
b
Haplotype
frequency
Test statistic
(haplotype
t-statistic)
Allele
p-value
a
Global
p-value
HLA-only
haplotype
frequency
Test statistic
(haplotype
t-statistic)
Allele
p-value
a
Global
p-value
A-C-B-RS2857602-RS2857708-RS915654-RS2844482-RS1041981-RS1799964-RS1799724-RS1800629-RS2256965-RS2256974
IFN-c 0.759 0.345
*03*04*35-AGTGCAGGAC 0.015 1.58 0.115 0.016 2.32 0.020
IL-2 0.235 0.299
*02*03*15-AAAACGGGGC 0.026 1.65 0.100 0.039 0.61 0.545
*02*07*07-GGTGCAGGAC 0.035 22.12 0.035 0.034 21.45 0.149
IL-6 0.617 0.239
*01*06*57-AGTGCGGGGC 0.012 22.01 0.045 0.012 21.95 0.052
*24*07*07-GGTGCAGGAC 0.016 1.49 0.137 0.018 2.64 0.009
TNF-a 0.835 0.310
*01*07*08-AGTGAAGAGC 0.080 1.58 0.114 0.086 1.44 0.151
*29*16*44-GGTGCAGGAC 0.022 2.30 0.022 0.023 2.35 0.019
GM-CSF 0.888 0.744
*02*07*07-GGTGCAGGAC 0.035 1.60 0.109 0.034 0.91 0.365
Only haplotypes with estimated frequencies $0.01 and p-values #0.15 are presented.
aHaplotype effects estimated using a haplotype t-statistic that assesses associations of cytokine levels across haplotypes. Allele p-value compares the haplotype of
interest to all other haplotypes combined. Statistically significant findings (p,0.05) are shown in bold. Analyses adjust for age at blood draw, gender, race, age at first
rubella vaccine, age at second rubella vaccine, and cohort status.
bCommon SNPs from the LTA gene: [rs2857602 (A.G), rs2857708 (G.A), rs915654 (T.A), rs2844482 (G.A), rs1041981 (C.A), rs1799964 (A.G), rs1799724 (G.A)]; TNF
gene: rs1800629 (G.A); LST1 gene: [rs2256965 (G.A), and rs2256974 (C.A)].
doi:10.1371/journal.pone.0011806.t003
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DPB1*04 (p=0.098) showed only a marginal association, while the
A*02-C*03-B*15 (p=0.15) haplotype demonstrated no trend. In
contrast, the A*03-C*07-B*07-GGTGCAGGAC haplotype (p=
0.02) trended with a weaker rubella antibody response. Likewise,
the HLA-only A*03-C*07-B*07 haplotype (p=0.01) was associated
with a higher humoral immune response. Thus, inclusion of
polymorphisms for LTA, TNF, and LST1 candidate genes into this
specific HLA haplotype did not alter the strength of the association.
This outcome is in agreement with our recent study demonstrating
the association of A*03-C*07-B*07 and DRB1*04-DQB1*03-
DPB1*04 haplotypes with rubella-specific antibodies [20] along
with other earlier studies demonstrating DR3 and DR4 restricted
T-cell and B-cell responses to rubella virus antigens [25], as well
as defined class I A*3 restricted immune responses to rubella
[26]. Nepom et al. [27] also demonstrated HLA-DR3 and DR4
restriction of rubella E1 peptides and commented that such
analyses ‘‘provide a direct approach for selecting antigenic
peptides useful for epitope-based vaccines targeted to multiple
HLA types’’. Our results imply that several genes in the class III
region are involved in regulating humoral immune responses to
rubella vaccine, and that some signature gene haplotypes can
potentially be used to characterize the spectrum of rubella-
specific IgG secretion. Further studies need to be performed in
larger and other racially diverse populations to more fully
investigate the role of these genetic haplotypes (and potential
causal variants) in vaccine-induced humoral immune responses.
Since cytokines are important for the development and shaping
of innate and adaptive immune responses to rubella, we examined
associations between extended haplotypes and rubella virus-
specific cytokine (IFN-c, IL-2, IL-6, TNF-a, and GM-CSF)
secretion levels. Interestingly, for the Th1 cytokine IFN-c,w e
found evidence for lower levels of IFN-c secretion associated
with the extended LTA-TNF-LST1-DRB1-DQA1-DQB1-DPA1-
DPB1 haplotypes. In particular, the haplotype AGTGAAGAG-
C-DRB1*15-DQA1*01-DQB1*06-DPA1*01-DPB1*04 (p=0.04)
was found to trend with decreased rubella-specific IFN-c secretion
levels, while the AGAGAAGGGA-DRB1*13-DQA1*01-DQB1*
06-DPA1*01-DPB1*04 haplotype was significantly associated with
lower IFN-c response (p=0.006); however, the global test did not
reach statistical significance, which may be a statistical power issue
resolvable with larger cohort sizes. When all class II HLA-only
haplotypes were compared across cytokine immune responses,
we found no HLA haplotypes associated with IFN-c response.
These results imply that genetic variation in the telomeric class III
region of the HLA may play a role in modulating IFN-c immune
responses to rubella and are worthy of further investigation.
The haplotypic background DRB1*04-DQA1*03-DQB1*03-
DPA1*01-DPB1*04 revealed suggestive associations between both
higher IFN-c (GGTGCAGGAC-DRB1*04-DQA1*03-DQB1*03-
Table 4. Associations between extended LTA-TNF-LST1-class II HLA haplotypes and class II HLA-only haplotypes, and rubella-
specific cytokine responses.
Cytokine Haplotype
b
Haplotype
frequency
Test statistic
(haplotype
t-statistic)
Allele
p-value
a
Global
p-value
HLA-only
haplotype
frequency
Test statistic
(haplotype
t-statistic)
Allele
p-value
a
Global
p-value
RS2857602-RS2857708-RS915654-RS2844482-RS1041981-RS1799964-RS1799724-RS1800629-RS2256965-RS2256974-DRB1-DQA1-DQB1-DPA1-DPB1
IFN-c 0.409 0.615
AGTGCAGGAC-*01*01*05*01*04 0.014 1.63 0.103 0.055 0.50 0.620
AGTGAAGAGC-*15*01*06*01*04 0.011 22.01 0.044 0.097 20.35 0.723
AGAGAAGGGA-*13*01*06*01*04 0.012 22.73 0.006 0.042 21.83 0.068
GGTGCAGGAC-*04*03*03*01*04 0.023 2.09 0.037 0.100 1.13 0.259
IL-2 0.135 0.151
AGAGAAGGGA- *04*03*03*01*04 0.038 2.49 0.013 0.100 2.87 0.004
AGAGAAGGGA-*13*01*06*01*04 0.012 21.56 0.118 0.042 21.37 0.172
AAAACGGGGC-*04*03*03*01*04 0.024 1.84 0.066 0.100 2.87 0.004
GGTGCAGGAC-*07*02*02*01*04 0.023 1.95 0.051 0.027 1.86 0.064
IL-6 0.053 0.816
AGTGAAGAGC-*03*05*02*01*04 0.042 21.83 0.068 0.049 22.07 0.039
AGTGAAGAGC-*15*01*06*01*04 0.011 1.95 0.052 0.097 0.53 0.597
AGAGAAGGGA-*13*01*06*01*04 0.012 1.64 0.101 0.042 0.72 0.469
AAAACGGGGC-*01*01*05*01*04 0.022 22.53 0.012 0.055 21.38 0.169
TNF-a 0.610 0.446
AGTGCGGGGC-*07*02*03*01*04 0.013 21.64 0.101 0.014 21.86 0.064
GM-CSF 0.642 0.910
AAAACGGGGC-*01*01*05*01*04 0.022 22.09 0.037 0.055 20.53 0.597
Only haplotypes with estimated frequencies $0.01 and p-values #0.15 are presented.
aHaplotype effects estimated using a haplotype t-statistic that assesses associations of cytokine levels across haplotypes. Allele p-value compares the haplotype of
interest to all other haplotypes combined. Statistically significant findings (p,0.05) are shown in bold. Analyses adjust for age at blood draw, gender, race, age at first
rubella vaccine, age at second rubella vaccine, and cohort status.
bCommon SNPs from the LTA gene: [rs2857602 (A.G), rs2857708 (G.A), rs915654 (T.A), rs2844482 (G.A), rs1041981 (C.A), rs1799964 (A.G), rs1799724 (G.A)]; TNF
gene: rs1800629 (G.A); LST1 gene: [rs2256965 (G.A), and rs2256974 (C.A)].
doi:10.1371/journal.pone.0011806.t004
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DRB1*04-DQA1*03-DQB1*03-DPA1*01-DPB1*04, p=0.01) ru-
bella-specific secretion. In contrast, class II HLA-only DRB1*04-
DQA1*03-DQB1*03-DPA1*01-DPB1*04 (p=0.004) haplotype
was observed to be associated with increased rubella-specific IL-
2 secretion levels, suggesting that LTA-TNF-LST1 SNPs are not
strongly contributing to the effect of IL-2 response associations.
We also found potential associations with lower rubella virus-
specific IL-2 secretion on the class I haplotypic background A*02-
C*07-B*07. Specifically, the extended A*02-C*07-B*07-GGT-
GCAGGAChaplotype (p=0.03) was found to be associated with
lower IL-2 secretion. No associations were found between class I
HLA-only haplotypes and rubella-specific IL-2 responses.
We found novel potential associations with the class I A*01-C*07-
B*08 and class II DRB1*03-DQA1*05-DQB1*02-DPA1*01-
DPB1*04 haplotype containing a set of ten-SNPs and the inflamma-
tory cytokine TNF-a. Specifically, haplotypes A*01-C*07-B*08-
AGTGAAGAGC(p=0.01) and A*01-C*07-B*08-AGTGAAGAGC-
DRB1*03-DQA1*05-DQB1*02-DPA1*01-DPB1*04 (p=0.01) were
associated with increased rubella-specific TNF-a secretion, though the
class I-class II HLA-only A*01-C*07-B*08-DRB1*03-DQA1*05-
DQB1*02-DPA1*01-DPB1*04 (p=0.009) haplotype was observed to
be significantly associated with increased rubella-specific TNF-a
secretion levels. Furthermore, individual class I and class II HLA-
only haplotypes demonstrated trends with lower and higher rubella-
specific IFN-c responses; A*03-C*07-B*07-DRB1*15-DQA1*01-
DQB1*06-DPA1*01-DPB1*04 (p=0.01) and A*02-C*07-B*07-
DRB1*15-DQA1*01-DQB1*06-DPA1*01-DPB1*04 (p=0.02), re-
spectively. Thus, this association was mostly driven by HLA gene
polymorphisms and not byt h eL T A - T N F - L S T 1S N P sper se.T h e s e
results are very consistent with the important roles that both HLA and
cytokines play in the rubella immunity.
Because the class III region of the HLA is characterized by
strong and extended linkage disequilibrium (LD), these findings
probably reflect the underlying LD patterns on these haplotypes
[28]. The LD pattern could be very diverse on specific DRB1-
DQA1-DQB1-DPA1-DPB1 haplotypes. It is also possible that
other genes in LD with the HLA genes on chromosome 6 are
important in influencing vaccine immune responses.
It should be noted that we have examined a reasonably large
collection of potential associations in this work, including three
different classes of extended haplotypes (HLA class I plus SNPs,
HLA class II plus SNPs, HLA class I and II combined plus SNPs)
and six distinct outcomes. We have attempted to apply one level of
control to these comparisons by performing a global test of
significance for all haplotypes of a given class for each outcome. By
performing this first-pass assessment, we are able to control false
positives for any given outcome by considering significant only
those haplotype associations whose global test is also significant.
However, additional care should be exercised given that 18 global
tests were performed. Using a 0.05 level of significance, on average
there should be 0.9 significant global tests that reach significance,
and we observed a single global p-value that reached that level of
significance. However, 1.8 global tests would be expected to be
significant at the 0.1 level of significance while we observed a total
of 3 – nearly twice the expected. We identified a total of 33
extended haplotypes with frequencies greater than or equal to
0.01:12 from HLA class I, 15 from HLA class II, and 6 from HLA
class I and II combined. Ignoring the global tests and proceeding
with haplotype-specific analyses for each of the six outcomes
would have resulted in a total of 198 tests of association. It is
important to note that after controlling for multiple testing using a
Bonferroni correction (a conservative testing approach due to the
correlational structure of both the outcomes and the haplotypes),
Table 5. Associations between extended class I HLA-LTA-TNF-LST1-class II HLA haplotypes and class I-class II HLA-only haplotypes,
and rubella-specific cytokine responses.
Cytokine Haplotype
b
Haplotype
frequency
Test statistic
(haplotype
t-statistic)
Allele
p-value
a
Global
p-value
HLA-only
haplotype
frequency
Test statistic
(haplotype
t-statistic)
Allele
p-value
a
Global
p-value
A-C-B-RS2857602-RS2857708-RS915654-RS2844482-RS1041981-RS1799964-RS1799724-RS1800629-RS2256965-RS2256974-DRB1-DQA1-DQB1-DPA1-DPB1
IFN-c 0.597 0.242
*02*07*07-GGTGCAGGAC-
*15*01*06*01*04
0.019 1.56 0.120 0.019 2.26 0.024
*03*07*07-GGTGCAGGAC-
*15*01*06*01*04
0.032 21.73 0.084 0.034 22.57 0.010
IL-2 0.446 0.209
*02*07*07-GGTGCAGGAC-
*15*01*06*01*04
0.019 21.52 0.129 0.019 21.80 0.073
IL-6 0.965 0.943
TNF-a 0.059 0.042
*01*07*08-AGTGAAGAGC-
*03*05*02*01*04
0.038 2.53 0.012 0.038 2.64 0.009
GM-CSF 0.382 0.445
*01*07*08-AGTGAAGAGC-
*03*05*02*01*04
0.038 1.55 0.123 0.038 1.65 0.100
Only haplotypes with estimated frequencies $0.01 and p-values #0.15 are presented.
aHaplotype effects estimated using a haplotype t-statistic that assesses associations of cytokine levels across haplotypes. Allele p-value compares the haplotype of
interest to all other haplotypes combined. Statistically significant findings (p,0.05) are shown in bold. Analyses adjust for age at blood draw, gender, race, age at first
rubella vaccine, age at second rubella vaccine, and cohort status.
bCommon SNPs from the LTA gene: [rs2857602 (A.G), rs2857708 (G.A), rs915654 (T.A), rs2844482 (G.A), rs1041981 (C.A), rs1799964 (A.G), rs1799724 (G.A)]; TNF
gene: rs1800629 (G.A); LST1 gene: [rs2256965 (G.A), and rs2256974 (C.A)].
doi:10.1371/journal.pone.0011806.t005
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at the p=0.05 level.
While it is possible that some of the results reported here are
false positives, there is a real chance that we have not identified
all of the potentially true results. For instance, with a total of 714
subjects providing the data to test the association between an
outcome and 15 haplotypes formed from one set of loci, there is
80% power to detect associations if the haplotypes describe 2.7%,
or 2.2% of the variability in the outcome if the type I error level is
set at 0.05 or 0.10. These are rather large effect sizes; for
instance, a haplotype with a frequency of 2% would need to be
associated with a greater than 2-fold difference in antibody levels
in order to describe an association of this magnitude. Therefore,
while there is a potential for false positives among those identified
here, it is also possible that important true associations could be
missed. There were also associations that were found in extended
haplotypes but not in HLA-only haplotypes and vice versa. In
addition, the percent of variability in the immune response
measures explained by the haplotypes was modest, even for the
two models with statistically significant global tests (r-
squared=0.80% for the association of antibody levels with the
combined class I and class II haplotype, and 4.98% for the class
II only extended haplotype). This is likely to be typical for multi-
allelic models of complex phenotypic traits such as immune
responses. For all these reasons, the results described herein
should be considered discovery in nature. It is important that
further studies be performed to replicate, and possibly extend, the
findings reported here.
We propose to test the hypothesis that non-HLA variants
contribute information above and beyond the HLA associations
and that inclusion of class III genes in extended class I-class II gene
haplotypes provides additional information beyond HLA alone.
We have examined associations between variations in an extended
genomic region surrounding the HLA complex and have observed
associations between haplotypes spanning the region flanked by
the class I and class II loci and rubella vaccine immunity.
Importantly, we found significant associations between higher
rubella antibody levels and SNPs located within the class I-class II
loci on the A*02-C*03-B*15-DRB1*04-DQA1*03-DQB1*03-
DPA1*01-DPB1*04 haplotypic background. It is possible that this
haplotype pattern marks other (untyped) polymorphic variants or
regions in LD, such as HLA-B associated transcripts (BAT3,
BAT2 and BAT1), allograft inhibitory factor 1 (AIF-1), natural
cytotoxicity triggering receptor (NCR3), lymphotoxin beta (LTB),
the MHC class I chain-related gene A (MICA), nuclear factor of
kB inhibitor-like polypeptide 1 (NFKBIL 1), complement
component C4 and/or others. As genetic variants may function
in a complementary manner to determine the outcome of vaccine-
induced immune responses, it is logical to propose that the
observed antibody level effects in our study may be an outcome of
combinations of HLA/SNP-defined alleles, including multigenic
or complementation effects. Additional population-based replica-
tion studies of larger size are needed in order to assess the
association of antibody variations in individuals with this
haplotype diversity. Potential extended haplotype associations
with variations in rubella vaccine-induced cytokine secreted levels
in our study population may also implicate an immunological role
of the proteins encoded by the HLA (A-C-B)-LTA-TNF-LST1-
HLA (DRB1-DQA1-DQB1-DPA1-DPB1) gene cluster in immune
response to rubella vaccine. Genetically determined variations in
cytokine secretion levels could influence both innate and adaptive
immunity to rubella. Future studies should concentrate on
functional characterization of these and other replicated gene
products with respect to immunological roles. We plan on
confirming these haplotypes in a larger independent replication
cohort to validate the findings and to elucidate the functional
aspects of these genetic variants.
Our study further demonstrates that HLA genes play a
dominant role in immune responses to rubella vaccine. Our study
may also suggest the existence of additional immune response
candidate genetic polymorphisms situated in the extended HLA
region, in addition to the known HLA allelic haplotypes, that may
play important roles in regulating immune responses. This new
information as well as future studies will help increase our
understanding of the genetic factors underlying rubella vaccine-
induced immunity and could be useful in the design of new rubella
vaccines. Understanding the basis for immune response genotype/
phenotype associations further informs knowledge regarding
vaccine immune response heterogeneity, and allows the develop-
ment of directed methods for personalized vaccines [24,29].
Materials and Methods
Ethics Statement
This study complied with the human experimentation guide-
lines of the United States Department of Health and Human
Services, and all enrolled subjects or their parents provided
written, informed consent, as well as written assent by age-
appropriate children. The work presented here was approved by
the Institutional Review Board at the Mayo Clinic under Protocol
number 06-002783.
Study Subjects
As described elsewhere, between 2001 and 2002, we enrolled
346 healthy adolescents (age 12 to 18 years) in Rochester,
Minnesota [30]. Three hundred and forty-two parents agreed
to allow their adolescents from this study to take part in a
second rubella vaccine study (first cohort). From 2006 to 2007,
we enrolled another cohort of 396 healthy adolescents and
young adults (age 11 to 19 years) in Rochester, Minnesota
(second cohort). All 738 participants (combined cohort) had
documentation of having received two doses of measles-
mumps-rubella-II (MMR-II) vaccine containing the attenuated
RA27/3 Wistar strain of rubella virus (Merck) [20]. No known
circulating rubella virus was observed since the earliest year of
birth for any subject in our geographic area. While 738
children and young adults were enrolled in the study,
genotyping data for SNPs and HLA alleles were available for
only 714 subjects (Table 1).
Antibody Measurement
We assayed all subjects for quantitative levels of rubella virus-
specific IgG antibodies using a whole virus rubella-specific
chemiluminescent immunoassay (Beckman Coulter Access, Full-
erton, CA) according to the manufacturer’s instructions. The limit
of detection for this assay was 0.5 IU/ml and the coefficient of
variation of this assay in our laboratory was 6%.
Genotyping Methods
DNA was extracted from fresh heparinized blood samples
(n=738) by conventional techniques using the PuregeneH
extraction kit (Gentra Systems). Class I HLA-A, -B and -C allele
typing was performed using High Resolution SSP (sequence-
specific primer) A, B, and C UniTray typing kits, respectively. Any
ambiguities were resolved using the Forensic Analytical sequen-
cing kit and AmbiSolv
TM when needed (Invitrogen). Class II HLA
typing was performed with high resolution DRB1 SSP, DQA1
SSP, DQB1 SSP, DPA1 SSP, and DPB1 SSP UnitrayH typing kits
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followed by AmbiSolv
TM when needed and analyzed using
MatchTools software. All reactions were run with negative
controls, and every fiftieth PCR reaction was repeated for quality
control. DNA samples were also genotyped for candidate SNPs
selected from immune response genes using a custom designed
768-plex Illumina GoldenGate
TM assay (Illumina Inc., San Diego,
CA) along with SNPs selected from LTA (rs2857602, rs2857708,
rs915654, rs2844482, rs1041981, rs1799964, rs1799724), TNF
(rs1800629) and LST1 (rs2256965, rs2256974) gene families. Not
all LTA, TNF and LST1 SNPs were genotyped due to different
selection strategies and lack of multiplexing abilities in the
genotyping system. SNP-specific deviation from Hardy-Weinberg
Equilibrium (HWE) was tested and no LTA, TNF or LST1 SNPs
displayed violations of HWE (p,0.001). Subject exclusions were
made on the basis of DNA quality (n=6), complete genotyping
failure (n=4) and low call rates below 95% (n=14), leaving a total
of 714 subjects in the study.
Cytokine Assays
Cytokine IFN-c, IL-2, IL-6, TNF-a, and GM-CSF secretion
levels in response to rubella virus stimulation (W-Therien strain,
gift from Dr. Teryl Frey, Georgia State University) were
determined in PBMC culture supernatants by ELISA. We used
previously optimized conditions specific for each cytokine in terms
of the time of incubation and amount of virus [multiplicity of
infection (MOI)] [21]. We quantitatively determined rubella-
specific cytokine responses in cell-free supernatants by ELISA
following the manufacturer’s protocol (BD Biosciences Pharmin-
gen, San Diego, CA). For all cytokine outcomes, we obtained three
rubella virus-stimulated measures and three unstimulated mea-
sures. We subtracted the median background levels from
unstimulated control cell cultures from the median rubella-
induced responses to calculate corrected secretion values.
Statistical Methods
We examined the following outcomes: a measure of circulating
rubella IgG antibodies (measured in units of IU/ml) and five
measures of rubella virus-specific in vitro cytokine secretion (IFN-c,
IL-2, IL-6, TNF-a, and GM-CSF, each measured in units of pg/
ml). Per manufacturer specifications, antibody level assays resulted
in one observation per subject. In contrast, assessment of cytokine
secretion resulted in six measures per individual: three unstimu-
lated and three rubella virus-stimulated measures. In order to
describe these outcomes, a single value per individual was
obtained by subtracting the medians of the three unstimulated
values from the median of the three stimulated values. Data were
descriptively summarized across individuals using frequencies and
percentages for all categorical variables, and medians and
interquartile ranges (IQRs) for continuous variables. Extended
haplotypes were constructed using the three HLA class I loci (A, C,
and B); seven common SNPs from the LTA gene (rs2857602,
rs2857708, rs915654, rs2844482, rs1041981, rs1799964,
rs1799724); TNF SNP rs1800629; two SNPs from the LST1 gene
(rs2256965, rs2256974); and five HLA class II loci (DRB1, DQA1,
DQB1, DPA1, and DPB1) (Figure 1). Design variables were
created for individual haplotypes assuming an ordinal effect on
immune response. Haplotype frequencies based on SNP alleles
and two-digit HLA alleles were created using a maximum
likelihood approach. Three sets of extended haplotypes were
considered: one containing the three HLA class I loci and the set
of SNPs, one containing the class II loci and the candidate SNPs
and, and one containing both class I and class II loci with the set of
SNPs. Because pedigree data were unavailable and each
individual’s linkage phase is unknown, there may be multiple
pairs of haplotypes which are consistent with the observed
genotypes. Posterior probabilities of all possible haplotypes for
an individual, conditional on the observed genotypes, were
estimated using an expectation-maximization (EM) algorithm
implemented in the Haplo.Stats package [31], using the default
setting for batch size, maximum number of iterations and
convergence criteria. These posterior probabilities were used to
construct an expected design matrix that contained as variables
the expected number of copies of each haplotype carried by each
individual. These variables in the expected design matrix range
from 0 to 2, and make it possible to test for haplotype-outcome
associations while accounting for phase ambiguity. Because of the
imprecision involved in estimating the effects of low-frequency
haplotypes, we retained only those occurring in our entire cohort
with an estimated frequency of greater than 1%.
Formal associations of the six different immune response levels
with the haplotype design variables were evaluated using linear
regression models. Simple linear models were used to examine
associations with antibody levels, whereas repeated measures
approaches were implemented for the cytokine secretion variables.
The repeated measures method improved statistical efficiency by
enabling analyses that simultaneously included all six observed
measurements. To assess haplotype associations with in vitro
changes in cytokine immune response from an unstimulated to
stimulated environment within this repeated measures framework,
we included in the statistical model the design variable(s) of
interest, an indicator of stimulation status, and the resulting
interaction term(s). The strength of association was then formally
tested by examining the statistical significance of the interaction
term(s). We accounted for the likelihood of intra-subject correla-
tions of immune response values by modeling an unstructured
variance-covariance matrix within subjects.
Differences in immune response associated with a given set of
common extended haplotypes were first simultaneously tested for
statistical significance. This was accomplished by including all
haplotype design variables with an estimated frequency greater
than 1% in the linear regression model and assessing their
combined effect on the immune response outcome using a
multiple degree-of-freedom test. We estimated the proportion of
variability in the immune response outcome attributable to the set
of haplotypes by calculating the generalized R
2 statistic which
compared models with and without the haplotype design variables
[32]. Following these global tests, we examined individual
haplotype effects. For these tests, each design variable - and for
the cytokine secretion data, stimulation status and the correspond-
ing interaction term - was included in a separate linear regression
analysis, effectively comparing immune response levels for the
haplotype of interest against all others combined. This series of
tests was performed in the spirit of Fisher’s protected least
significant difference test; individual associations were not
considered statistically significant in the absence of global
significance. Due to phase ambiguity, haplotype-specific descrip-
tive summaries using medians and inter-quartile ranges could not
be obtained for secreted cytokines. Instead, t-statistics were
calculated reflecting the direction, and relative magnitude, of the
estimated haplotypic effect on the immune response.
In order to assess the excess contribution of the SNPs on
haplotype associations, over and above the HLA effects, we
reconstructed and retested the haplotypes using only the HLA
alleles. This resulted in three reduced haplotypes: one containing
only the class I alleles, one containing only the class II alleles, and
one containing both class I and class II alleles. All analyses
described above were performed while adjusting for covariates
Extended Gene Haplotypes
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variables were included in all models: age at enrollment, race,
gender, age at first rubella vaccination, age at second rubella
vaccination, and cohort status (first versus second). Data
transformations were used to correct for data skewness in all
linear regression models. We used a simple log-transformation for
antibody level data. This approach was not feasible for the
cytokine secretion data due to the existence of zero or negative
values. Thus, for these variables an inverse cumulative normal
(probit) transformation was used. All statistical tests were two-
sided, and all analyses were carried out using SAS (SAS Institute,
Inc., Cary, NC) and the Haplo.Stats software package as
implemented in S-Plus (Insightful Corp., Seattle, WA).
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